The packaging label for ITVISMA (onasemnogene abeparvovec-brve) injection, suspension displays the product name and active ingredient prominently. It indicates a strength of 1.2 x 10^14 vector genomes per 3 mL (4 x 10^13 vector genomes per mL). The label notes that this sterile suspension is for intrathecal injection only, provided as a single-dose vial, and must be used within 14 days of receipt. The manufacturer is Novartis Innovative Technologies Inc. The label also includes storage instructions to not shake or freeze and contains dosage and handling information.*